BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012;5:199-207. [PMID: 22570680 DOI: 10.1177/1756283x11430859] [Cited by in Crossref: 108] [Cited by in F6Publishing: 52] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Drescher HK, Weiskirchen S, Weiskirchen R. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Cells 2019;8:E845. [PMID: 31394730 DOI: 10.3390/cells8080845] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 22.5] [Reference Citation Analysis]
2 Hua G, Zein N, Paulen L, Chambon P. The glucocorticoid receptor agonistic modulators CpdX and CpdX-D3 do not generate the debilitating effects of synthetic glucocorticoids. Proc Natl Acad Sci U S A 2019;116:14200-9. [PMID: 31221758 DOI: 10.1073/pnas.1908264116] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Deguise MO, Baranello G, Mastella C, Beauvais A, Michaud J, Leone A, De Amicis R, Battezzati A, Dunham C, Selby K, Warman Chardon J, McMillan HJ, Huang YT, Courtney NL, Mole AJ, Kubinski S, Claus P, Murray LM, Bowerman M, Gillingwater TH, Bertoli S, Parson SH, Kothary R. Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Ann Clin Transl Neurol 2019;6:1519-32. [PMID: 31402618 DOI: 10.1002/acn3.50855] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 17.5] [Reference Citation Analysis]
4 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 25.5] [Reference Citation Analysis]
5 Gasim GI, Elshehri FM, Kheidr M, Alshubaily FK, ElZaki EM, Musa IR. The Use of Computed Tomography in the Diagnosis of Fatty Liver and Abdominal Fat Distribution among a Saudi Population. Open Access Maced J Med Sci 2017;5:762-5. [PMID: 29104685 DOI: 10.3889/oamjms.2017.187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Hamlin AN, Chinnarasu S, Ding Y, Xian X, Herz J, Jaeschke A, Hui DY. Low-density lipoprotein receptor-related protein-1 dysfunction synergizes with dietary cholesterol to accelerate steatohepatitis progression. J Biol Chem 2018;293:9674-84. [PMID: 29752404 DOI: 10.1074/jbc.RA118.001952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
7 Yıldız Y, Sivri HS. Inborn errors of metabolism in the differential diagnosis of fatty liver disease. Turk J Gastroenterol 2020;31:3-16. [PMID: 32009609 DOI: 10.5152/tjg.2019.19367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
8 Scherer T, Lindtner C, O'Hare J, Hackl M, Zielinski E, Freudenthaler A, Baumgartner-Parzer S, Tödter K, Heeren J, Krššák M, Scheja L, Fürnsinn C, Buettner C. Insulin Regulates Hepatic Triglyceride Secretion and Lipid Content via Signaling in the Brain. Diabetes 2016;65:1511-20. [PMID: 26861781 DOI: 10.2337/db15-1552] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
9 Hagström H, Hemmingsson T, Discacciati A, Andreasson A. Risk Behaviors Associated with Alcohol Consumption Predict Future Severe Liver Disease. Dig Dis Sci 2019;64:2014-23. [PMID: 30761471 DOI: 10.1007/s10620-019-05509-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
10 Ashtari S, Pourhoseingholi MA, Zali MR. Non-alcohol fatty liver disease in Asia: Prevention and planning. World J Hepatol. 2015;7:1788-1796. [PMID: 26167252 DOI: 10.4254/wjh.v7.i13.1788] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
11 Lee HL, Bae SH, Jang B, Hwang S, Yang H, Nam HC, Sung PS, Lee SW, Jang JW, Choi JY, Han NI, Song BJ, Lee JW, Yoon SK. Reactivation of Hepatitis C Virus and Its Clinical Outcomes in Patients Treated with Systemic Chemotherapy or Immunosuppressive Therapy.Gut Liver. 2017;11:870-877. [PMID: 28750484 DOI: 10.5009/gnl16434] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
12 Kosmalski M, Mokros Ł, Kuna P, Witusik A, Pietras T. Changes in the immune system - the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease. Cent Eur J Immunol 2018;43:231-9. [PMID: 30135638 DOI: 10.5114/ceji.2018.77395] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
13 Pires de Mello CP, Carmona-Moran C, McAleer CW, Perez J, Coln EA, Long CJ, Oleaga C, Riu A, Note R, Teissier S, Langer J, Hickman JJ. Microphysiological heart-liver body-on-a-chip system with a skin mimic for evaluating topical drug delivery. Lab Chip 2020;20:749-59. [PMID: 31970354 DOI: 10.1039/c9lc00861f] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 16.0] [Reference Citation Analysis]
14 Yang YM, Fukui M, Wang Z, Miao F, Karriker MJ, Seki E. Interventional Potential of Recombinant Feline Hepatocyte Growth Factor in a Mouse Model of Non-alcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2018;9:378. [PMID: 30083132 DOI: 10.3389/fendo.2018.00378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R, Seki E. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2014;59:483-495. [PMID: 23996730 DOI: 10.1002/hep.26698] [Cited by in Crossref: 138] [Cited by in F6Publishing: 118] [Article Influence: 17.3] [Reference Citation Analysis]
16 Goh GB, Leow WQ, Liang S, Wan WK, Lim TKH, Tan CK, Chang PE. Quantification of hepatic steatosis in chronic liver disease using novel automated method of second harmonic generation and two-photon excited fluorescence. Sci Rep 2019;9:2975. [PMID: 30814650 DOI: 10.1038/s41598-019-39783-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Parafati M, Bae SH, Kirby RJ, Fitzek M, Iyer P, Engkvist O, Smith DM, Malany S. Pluripotent Stem Cell-Derived Hepatocytes Phenotypic Screening Reveals Small Molecules Targeting the CDK2/4-C/EBPα/DGAT2 Pathway Preventing ER-Stress Induced Lipid Accumulation. Int J Mol Sci 2020;21:E9557. [PMID: 33334026 DOI: 10.3390/ijms21249557] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Desai NK, Harney S, Raza R, Al-Ibraheemi A, Shillingford N, Mitchell PD, Jonas MM. Comparison of Controlled Attenuation Parameter and Liver Biopsy to Assess Hepatic Steatosis in Pediatric Patients. J Pediatr. 2016;173:160-164.e1. [PMID: 27039224 DOI: 10.1016/j.jpeds.2016.03.021] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
19 Ued Fda V, Weffort VR. Antioxidant vitamins in the context of nonalcoholic fatty liver disease in obese children and adolescents. Rev Paul Pediatr 2013;31:523-30. [PMID: 24473959 DOI: 10.1590/S0103-05822013000400016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Klaunig JE, Li X, Wang Z. Role of xenobiotics in the induction and progression of fatty liver disease. Toxicol Res (Camb) 2018;7:664-80. [PMID: 30090613 DOI: 10.1039/c7tx00326a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
21 Dumolt JH, Browne RW, Patel MS, Rideout TC. Malprogramming of Hepatic Lipid Metabolism due to Excessive Early Cholesterol Exposure in Adult Progeny. Mol Nutr Food Res 2019;63:e1800563. [PMID: 30447138 DOI: 10.1002/mnfr.201800563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Dunnick JK, Shockley KR, Pandiri AR, Kissling GE, Gerrish KE, Ton TV, Wilson RE, Brar SS, Brix AE, Waidyanatha S, Mutlu E, Morgan DL. PBDE-47 and PBDE mixture (DE-71) toxicities and liver transcriptomic changes at PND 22 after in utero/postnatal exposure in the rat. Arch Toxicol 2018;92:3415-33. [PMID: 30206662 DOI: 10.1007/s00204-018-2292-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
23 Martin GG, Chung S, Landrock D, Landrock KK, Dangott LJ, Peng X, Kaczocha M, Murphy EJ, Kier AB, Schroeder F. Female Mice are Resistant to Fabp1 Gene Ablation-Induced Alterations in Brain Endocannabinoid Levels. Lipids 2016;51:1007-20. [PMID: 27450559 DOI: 10.1007/s11745-016-4175-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
24 Damiani G, Leone S, Fajgenbaum K, Bragazzi NL, Pacifico A, Conic RR, Pigatto PD, Maiorana C, Poli P, Berti E, Pace MC, Malagoli P, Bettoli V, Fiore M. Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: A multi-center retrospective analysis. World J Hepatol 2019;11:391-401. [PMID: 31114643 DOI: 10.4254/wjh.v11.i4.391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
25 Pannala VR, Estes SK, Rahim M, Trenary I, O'Brien TP, Shiota C, Printz RL, Reifman J, Shiota M, Young JD, Wallqvist A. Toxicant-Induced Metabolic Alterations in Lipid and Amino Acid Pathways Are Predictive of Acute Liver Toxicity in Rats. Int J Mol Sci 2020;21:E8250. [PMID: 33158035 DOI: 10.3390/ijms21218250] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Dutta A, Sinha DK. Zebrafish lipid droplets regulate embryonic ATP homeostasis to power early development. Open Biol 2017;7:170063. [PMID: 28679548 DOI: 10.1098/rsob.170063] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
27 Ozturk A, Grajo JR, Gee MS, Benjamin A, Zubajlo RE, Thomenius KE, Anthony BW, Samir AE, Dhyani M. Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance. Ultrasound Med Biol 2018;44:2461-75. [PMID: 30232020 DOI: 10.1016/j.ultrasmedbio.2018.07.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 9.7] [Reference Citation Analysis]
28 Lee NY, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, Lee DY, Park TS, Park SH, Kim BK, Joung HC, Choi IS, Hong JT, Kim DJ, Han SH, Suk KT. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes 2020;11:882-99. [PMID: 31965894 DOI: 10.1080/19490976.2020.1712984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
29 Mehta R, Jeiran K, Koenig AB, Otgonsuren M, Goodman Z, Baranova A, Younossi Z. The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). BMC Med Genet 2016;17:63. [PMID: 27596100 DOI: 10.1186/s12881-016-0324-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
30 Dumolt JH, Patel MS, Rideout TC. Excessive early-life cholesterol exposure may have later-life consequences for nonalcoholic fatty liver disease. J Dev Orig Health Dis 2021;12:229-36. [PMID: 32290895 DOI: 10.1017/S2040174420000239] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Zhang J, Zhao Y, Xu C, Hong Y, Lu H, Wu J, Chen Y. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci Rep. 2014;4:5832. [PMID: 25060337 DOI: 10.1038/srep05832] [Cited by in Crossref: 72] [Cited by in F6Publishing: 77] [Article Influence: 10.3] [Reference Citation Analysis]
32 Hamlin AN, Basford JE, Jaeschke A, Hui DY. LRP1 Protein Deficiency Exacerbates Palmitate-induced Steatosis and Toxicity in Hepatocytes. J Biol Chem 2016;291:16610-9. [PMID: 27317662 DOI: 10.1074/jbc.M116.717744] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
33 Mogahed EA, Sayed AA, Khalifa SE, El-Hennawy A, El-Raziky MS. Causes of secondary non-alcoholic fatty liver disease in non-obese children below 10 years. Eur J Pediatr 2020;179:719-26. [PMID: 31897838 DOI: 10.1007/s00431-019-03551-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Huang H, McIntosh AL, Martin GG, Petrescu AD, Landrock KK, Landrock D, Kier AB, Schroeder F. Inhibitors of Fatty Acid Synthesis Induce PPAR α -Regulated Fatty Acid β -Oxidative Genes: Synergistic Roles of L-FABP and Glucose. PPAR Res 2013;2013:865604. [PMID: 23533380 DOI: 10.1155/2013/865604] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
35 Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep 2019;1:329-41. [PMID: 32039383 DOI: 10.1016/j.jhepr.2019.08.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
36 Ragucci E, Nguyen D, Lamerson M, Moraitis AG. Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma. Case Rep Endocrinol 2017;2017:6161348. [PMID: 29348947 DOI: 10.1155/2017/6161348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
37 Danford CJ, Connelly MA, Shalaurova I, Kim M, Herman MA, Nasser I, Otvos JD, Afdhal NH, Jiang ZG, Lai M. A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease. Hepatol Commun 2018;2:1467-78. [PMID: 30556036 DOI: 10.1002/hep4.1267] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
38 Pazoki R, Vujkovic M, Elliott J, Evangelou E, Gill D, Ghanbari M, van der Most PJ, Pinto RC, Wielscher M, Farlik M, Zuber V, de Knegt RJ, Snieder H, Uitterlinden AG, Lynch JA, Jiang X, Said S, Kaplan DE, Lee KM, Serper M, Carr RM, Tsao PS, Atkinson SR, Dehghan A, Tzoulaki I, Ikram MA, Herzig KH, Järvelin MR, Alizadeh BZ, O'Donnell CJ, Saleheen D, Voight BF, Chang KM, Thursz MR, Elliott P; Lifelines Cohort Study., VA Million Veteran Program. Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. Nat Commun 2021;12:2579. [PMID: 33972514 DOI: 10.1038/s41467-021-22338-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Jensen T, Niwa K, Hisatome I, Kanbay M, Andres-Hernando A, Roncal-Jimenez CA, Sato Y, Garcia G, Ohno M, Lanaspa MA, Johnson RJ, Kuwabara M. Increased Serum Uric Acid over five years is a Risk Factor for Developing Fatty Liver. Sci Rep. 2018;8:11735. [PMID: 30082907 DOI: 10.1038/s41598-018-30267-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
40 Kumar R, Mohan S. Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications. J Clin Transl Hepatol. 2017;5:216-223. [PMID: 28936403 DOI: 10.14218/jcth.2016.00068] [Cited by in Crossref: 17] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
41 Sewter R, Heaney S, Patterson A. Coffee Consumption and the Progression of NAFLD: A Systematic Review. Nutrients 2021;13:2381. [PMID: 34371891 DOI: 10.3390/nu13072381] [Reference Citation Analysis]
42 De Silva A, Nightingale JMD. Refeeding syndrome : physiological background and practical management. Frontline Gastroenterol 2020;11:404-9. [PMID: 32884632 DOI: 10.1136/flgastro-2018-101065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Danford CJ, Yao ZM, Jiang ZG. Non-alcoholic fatty liver disease: a narrative review of genetics. J Biomed Res 2018;32:389-400. [PMID: 30355853 DOI: 10.7555/JBR.32.20180045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
44 Wright AP, Desai AP, Bajpai S, King LY, Sahani DV, Corey KE. Gaps in recognition and evaluation of incidentally identified hepatic steatosis. Dig Dis Sci 2015;60:333-8. [PMID: 25190263 DOI: 10.1007/s10620-014-3346-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
45 Alhasson F, Seth RK, Sarkar S, Kimono DA, Albadrani MS, Dattaroy D, Chandrashekaran V, Scott GI, Raychoudhury S, Nagarkatti M, Nagarkatti P, Diehl AM, Chatterjee S. High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease. Redox Biol 2018;17:1-15. [PMID: 29660503 DOI: 10.1016/j.redox.2018.04.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
46 Yang L, Miura K, Zhang B, Matsushita H, Yang YM, Liang S, Song J, Roh YS, Seki E. TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice. Cell Mol Gastroenterol Hepatol 2017;3:469-83. [PMID: 28462384 DOI: 10.1016/j.jcmgh.2016.12.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
47 Bauer KC, Huus KE, Brown EM, Bozorgmehr T, Petersen C, Cirstea MS, Woodward SE, McCoy J, Hun J, Pamplona R, Ayala V, Finlay BB. Dietary Intervention Reverses Fatty Liver and Altered Gut Microbiota during Early-Life Undernutrition. mSystems 2020;5:e00499-20. [PMID: 32900869 DOI: 10.1128/mSystems.00499-20] [Reference Citation Analysis]
48 Mustapic S, Ziga S, Matic V, Bokun T, Radic B, Lucijanic M, Marusic S, Babic Z, Grgurevic I. Ultrasound Grade of Liver Steatosis Is Independently Associated with the Risk of Metabolic Syndrome. Can J Gastroenterol Hepatol 2018;2018:8490242. [PMID: 30211140 DOI: 10.1155/2018/8490242] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
49 Yousef MH, Al Juboori A, Albarrak AA, Ibdah JA, Tahan V. Fatty liver without a large "belly": Magnified review of non-alcoholic fatty liver disease in non-obese patients. World J Gastrointest Pathophysiol 2017;8:100-7. [PMID: 28868179 DOI: 10.4291/wjgp.v8.i3.100] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
50 Cho J, Lee I, Park DH, Kwak HB, Min K. Relationships between Socioeconomic Status, Handgrip Strength, and Non-Alcoholic Fatty Liver Disease in Middle-Aged Adults. Int J Environ Res Public Health 2021;18:1892. [PMID: 33669288 DOI: 10.3390/ijerph18041892] [Reference Citation Analysis]
51 Conlon BA, Beasley JM, Aebersold K, Jhangiani SS, Wylie-Rosett J. Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). Nutrients. 2013;5:4093-4114. [PMID: 24152749 DOI: 10.3390/nu5104093] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
52 Alogaili F, Chinnarasu S, Jaeschke A, Kranias EG, Hui DY. Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export. J Biol Chem 2020;295:4631-46. [PMID: 32079675 DOI: 10.1074/jbc.RA119.012361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]